Viking Therapeutics (VKTX) Other Working Capital Changes (2019 - 2026)
Viking Therapeutics (VKTX) reported Other Working Capital Changes of -$139000.0 for Q1 2026, down 7.75% on a YoY basis from -$150680.7 in Q1 2025, and down 19.83% sequentially from -$116000.0 in Q4 2025.
Viking Therapeutics (VKTX) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 8 years of Other Working Capital Changes data on file, last reported at -$139000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes fell 7.75% year-over-year to -$139000.0; the trailing twelve-month figure through Mar 2026 stood at -$515000.0 (down 16.25% YoY), and the FY2025 full-year result was -$505000.0, down 25.62% from the prior year.
- Other Working Capital Changes eased to -$139000.0 in Q1 2026, from -$116000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $9.6 million in Q1 2025 to a low of -$14.3 million in Q4 2025.
- A 5-year average of -$185470.6 and a median of $58000.0 in 2023 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes surged 196.51% in 2022 and slumped 206.02% in 2023, its largest moves.
- Tracing VKTX's Other Working Capital Changes over 5 years: stood at -$84000.0 in 2022, then retreated by 3.57% to -$87000.0 in 2023, then tumbled by 47.13% to -$128000.0 in 2024, then advanced by 9.38% to -$116000.0 in 2025, then retreated by 19.83% to -$139000.0 in 2026.
- Business Quant data shows VKTX's Other Working Capital Changes at -$139000.0 in Q1 2026, -$116000.0 in Q4 2025, and -$130000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -139,000.00 |
| Mar 31, 2026 | -139,000.00 |
| Mar 31, 2026 | -139,000.00 |
| Dec 31, 2025 | -116,000.00 |
| Dec 31, 2025 | -116,000.00 |
| Dec 31, 2025 | -116,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Jun 30, 2025 | -130,000.00 |
| Jun 30, 2025 | -130,000.00 |
| Jun 30, 2025 | -130,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Sep 30, 2024 | -96,000.00 |
| Sep 30, 2024 | -96,000.00 |